Reviewing XORTX Therapeutics (XRTX) & Its Rivals

XORTX Therapeutics (NASDAQ:XRTX) is one of 247 public companies in the “MED – DRUGS” industry, but how does it compare to its peers? We will compare XORTX Therapeutics to related businesses based on the strength of its institutional ownership, dividends, valuation, earnings, analyst recommendations, profitability and risk.

Analyst Ratings

This is a summary of recent recommendations and price targets for XORTX Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1	0	0	0	1.00
XORTX Therapeutics Competitors	2903	4060	10349	472	2.47

As a group, “MED – DRUGS” companies have a potential upside of 123.75%. Given XORTX Therapeutics’ peers stronger consensus rating and higher possible upside, analysts clearly believe XORTX Therapeutics has less favorable growth aspects than its peers.

Institutional and Insider Ownership

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 43.9% of shares of all “MED – DRUGS” companies are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by insiders. Comparatively, 13.5% of shares of all “MED – DRUGS” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

XORTX Therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, XORTX Therapeutics’ peers have a beta of -0.38, suggesting that their average share price is 138% less volatile than the S&P 500.

Earnings and Valuation

This table compares XORTX Therapeutics and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
XORTX Therapeutics	N/A	-$2.66 million	-0.95
XORTX Therapeutics Competitors	$1.21 billion	$101.67 million	-4.61

XORTX Therapeutics’ peers have higher revenue and earnings than XORTX Therapeutics. XORTX Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares XORTX Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-120.32%	-90.53%
XORTX Therapeutics Competitors	-22,657.45%	-150.68%	-22.88%

Summary

XORTX Therapeutics peers beat XORTX Therapeutics on 9 of the 13 factors compared.

About XORTX Therapeutics

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.